43 completed, 8 recruiting, 4 active not recruiting, 2 not yet recruiting. 28 Phase 3, 10 Phase 1, 10 Phase 2, 9 Phase 4, 3 Not applicable.
Follow ixekizumab: new trials by email Literature Review of ixekizumab trials Research Report on ixekizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of SB35 (Proposed Ixekizumab Biosimilar) to Taltz in Healthy Participants Ixekizumab - Healthy | Phase 1 | Recruiting | Samsung Bioepis Co., Ltd. | 174 | 2026-09-04 | 2026-10-14 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis Ixekizumab, Tirzepatide - Psoriatic Arthritis (PsA), Obesity & Overweight | Not applicable | Recruiting | NHS Greater Glasgow and Clyde | 45 | 2026-03-09 | 2026-05-04 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects Ixekizumab - Healthy Participants | Phase 1 | Active not recruiting | Celltrion | 218 | 2025-09-17 | 2025-12-31 |
| Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms Secukinumab, Bimekizumab, Ixekizumab - Psoriatic Arthritis, Depression | Recruiting | NHS Greater Glasgow and Clyde | 50 | 2025-06-02 | 2025-06-19 | |
| A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy Picankibart, Secukinumab, Placebo - Plaque Psoriasis | Phase 3 | Active not recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 308 | 2025-05-27 | 2026-03-25 |
| Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis Ixekizumab - Guttate Psoriasis | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2025-05-01 | 2025-02-10 |
| Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis Taltz - Idiopathic Subglottic Stenosis | Phase 2 | Completed | Yale University | 10 | 2025-02-20 | 2026-05-29 |
| Ixekizumab Versus Secukizumab in Over 70-year-old Patients with Psoriasis Ixekizumab, Secukizumab - Over 70-year-old Patients with Psoriasis | Not applicable | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2025-02-01 | 2025-02-06 |
| Proactive TDM Versus Standard Use of Biologics in Psoriasis Proactive TDM-based dosing of secukinumab, Proactive TDM-based dosing of ixekizumab, Proactive TDM-based dosing of guselkumab - Psoriasis Vulgaris | Phase 4 | Recruiting | University Hospital, Ghent | 210 | 2024-12-20 | 2026-03-04 |
| Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight Ixekizumab, Tirzepatide - Psoriasis, Obesity | Phase 3 | Completed | Eli Lilly and Company | 281 | 2024-09-30 | 2026-06-17 |
| Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight Ixekizumab, Tirzepatide - Psoriatic Arthritis, Obesity | Phase 3 | Completed | Eli Lilly and Company | 279 | 2024-09-24 | 2026-05-13 |
| A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India Ixekizumab - Plaque Psoriasis, Psoriatic Arthritis | Phase 4 | Completed | Eli Lilly and Company | 250 | 2023-06-27 | 2025-08-22 |
| Immunoclassification of Psoriasis: a Strategy for Precision Medicine adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate - Immunoclassification, Psoriasis | Not applicable | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2023-01-01 | 2024-01-12 |
| Ixekizumab Diabetes Intervention Trial (I-DIT) Ixekizumab, Placebo - Type1 Diabetes Mellitus | Phase 2 | Active not recruiting | Göteborg University | 127 | 2022-11-09 | 2026-04-27 |
| COVID-19 VaccinE Response in Rheumatology Patients Upadacitinib, Abatacept, Secukinumab - Rheumatoid Arthritis, Psoriatic Arthritis | Phase 4 | Completed | Jeffrey Curtis | 841 | 2021-11-15 | 2025-05-02 |
| Targeting IL-17A for Treatment-Resistant Depression Ixekizumab - Major Depressive Disorder | Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 7 | 2021-08-27 | 2025-05-20 |
| A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis Ixekizumab, Adalimumab - Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis | Phase 3 | Active not recruiting | Eli Lilly and Company | 101 | 2021-04-13 | 2026-08-12 |
| Survival TRial Using CytoKines in COVID-19 (STRUCK Trial) Ixekizumab, Aldesleukin, Colchicine - Covid19 | Phase 3 | Completed | University of Sao Paulo | 60 | 2021-01-05 | 2022-07-28 |
Showing 20 of 61. Sign in to see all of them.
Psoriasis (14) · Arthritis, Psoriatic (12) · Arthritis, Rheumatoid (6) · Spondylarthritis (6) · Spondylitis, Ankylosing (6) · Obesity (3) · Arthritis, Juvenile (2) · Axial Spondyloarthritis (2) · Depression (2) · Skin Diseases (2) · Bronchiolitis Obliterans Syndrome (1) · COVID-19 (1) · Cytokine Release Syndrome (1) · Depressive Disorder, Major (1) · Depressive Disorder, Treatment-Resistant (1)
Eli Lilly and Company (38) · Second Affiliated Hospital, Zhejiang University, School of Medicine (3) · NHS Greater Glasgow and Clyde (2) · Celltrion (1) · Göteborg University (1) · Icahn School of Medicine at Mount Sinai (1) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (1) · Jeffrey Curtis (1) · Mayo Clinic (1) · NYU Langone Health (1) · Ohio State University (1) · Oregon Health and Science University (1) · Radboud University Medical Center (1) · Samsung Bioepis Co., Ltd. (1) · Seoul National University Hospital (1)
United States (34) · Germany (17) · Poland (15) · Canada (14) · Netherlands (13) · United Kingdom (13) · Czechia (11) · Japan (11) · Mexico (11) · Spain (11) · Argentina (10) · France (10) · Puerto Rico (10) · South Korea (9) · Belgium (8)
Aaron Mangold, MD (1) · Benjamin Kaffenberger, MD (1) · Carl Goodyear, PhD, (1) · Chang-Keun Lee, MD (1) · Changhoon Lee, MD (1) · Dae Hyun Yu, MD (1) · Eduardo Ramacciotti, MD, PhD (1) · Elke de Jong, MD, PhD (1) · Esper Kallas, MD, PhD (1) · Eun Yeong Lee, MD (1) · Fernando Rodrigues, MD, PhD (1) · Gwan Gyu Song, MD (1)
PMID 35279805, PMID 37400681, PMID 35393269, PMID 36792107, PMID 38521874, PMID 26953848, PMID 27299809, PMID 31964419, PMID 35429281, PMID 36282526, PMID 38647975, PMID 40014255, PMID 40694276, PMID 41417207, PMID 26072109, PMID 28074446, PMID 30465321, PMID 30696483, PMID 30886974, PMID 31154634, PMID 31254223, PMID 31685553, PMID 32200512, PMID 32792421, PMID 32845588, PMID 33499913, PMID 34538257, PMID 34853086, PMID 35188180, PMID 35397092, PMID 35449322, PMID 38814433, PMID 38955921, PMID 42228347, PMID 22455413, PMID 24623718, PMID 25242558, PMID 25355284, PMID 25693783, PMID 26669919, PMID 27500949, PMID 27553214, PMID 27910156, PMID 28551073, PMID 29116597, PMID 29247148, PMID 29299340, PMID 29751001, PMID 29945203, PMID 30053162
2015 (8), 2016 (3), 2023 (2), 2018 (1), 2019 (1)